Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
Journal of Acquired Immune Deficiency Syndromes - United States
doi 10.1097/qai.0b013e3181ee3d82
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2010
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)